Amgen Inc.

Jason Charles O'Neill

Randal Robert Ketchem

Jiangchun Xu

Richard Jeffrey Armitage

Gunasekaran Kannan

William C Fanslow, Iii

Mark Edward Tometsko

Michelle Blake

Yu Zhang

Derek Evan Piper

Jennifer E Towne

Janet D Cheng

Yu Sun

Heather Cerne

Ian Nevin Foltz

Jeonghoon Sun

Mark Leo Michaels

Zhulun Wang

Randy Ira Hecht

Edward John Belouski

Jennitte LeAnn Stevens

Courtney Beers

Julia C Piasecki

Athena Sudom

Vishnu Chintalgattu

Taeweon Lee

Iii William C Fanslow

The application concerns tissue inhibitor of metalloproteinase 3 (TIMP-3) muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them; in particular, muteins of TIMP-3 with specific amino acid substitutions in order to introduce N-linked glycosylation sites.

Variants of tissue inhibitor or metalloprotienase type three (TIMP-3), compositions and methods

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.

BCMA antigen binding proteins

The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

BCMA Antigen binding proteins

There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.

Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods

Antigen binding proteins that bind to human IL-23 protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same as well as use of IL-23 antigen binding proteins for diagnostic and therapeutic purposes are also provided.

Human IL-23 antigen binding proteins

Antigen binding proteins that activate GITR are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided. The antigen binding proteins have value in therapeutic methods in which it is useful to stimulate GITR signaling, thereby inducing or enhancing an immune response in a subject. Accordingly, the antigen binding proteins have utility in a variety of immunotherapy treatments, including treatment of various cancers and infections.

GITR antigen binding proteins and methods of use thereof

Growing community of inventors

Brier, WA, United States of America

Jason Charles O'Neill